Samsung Bioepis sues again to invalidate Humira biosimilar
Intellectual Property 2022-06-30 2:57 pm By Cindy Cameronne | Sydney

Save(0) Please login to bookmark Username or Email Address Password Remember Me Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.